Case-control study on analgesics and nephropathy (SAN): protocol

Lothar A J Heinemann, Edeltraut Garbe, Michael Lewis, Fokko van der Woude, Helmut Graf, Lothar A J Heinemann, Edeltraut Garbe, Michael Lewis, Fokko van der Woude, Helmut Graf

Abstract

Background: The association between intake of non-phenacetin-containing analgesics and the occurrence of chronic renal failure is still controversially discussed. A new epidemiologic study was planned and conducted in Germany and Austria.

Methods/design: The objective of the international, multicenter case-control study was to evaluate the association between end-stage renal disease (ESRD) and use of non-phenacetin-containing analgesics with particular emphasis on combined formulations. A targeted sample of 1000 new (incident) dialysis patients, aged less than 50 years, was planned to recruit between January 1, 2001 and December 31, 2004. The age limit was chosen to avoid contamination of the study population with phenacetin-containing analgesics to the extent possible. Four control subjects per ESRD case, matched by age, sex, and region were selected from the population living in the region the case came from. Lifetime exposure to analgesics and potential renal risk factors were recorded in a single face-to-face interview. A set of aids was introduced to reinforce the memory of study participants. A standardized, pre-tested interview questionnaire (participants), a medical documentation sheet (physicians in dialysis centres), a logbook for all activities (dialysis centres) were used to collect the necessary data. Quality management consisted of the standardized procedures, (re-) training and supervision of interviewers, regular checks of all incoming data for completeness and plausibility. The study is scientifically independent and governed by a international Scientific Advisory Committee that bridged the gap between the sponsoring companies and the investigators. Also other advisory groups assisted the managing committee of the study. All relevant German and Austrian nephrological associations supported the study, and the study design was carefully reviewed and approved by the Kidney Foundation of Germany.

Discussion: The study is expected to answer the main research question by end 2005. There is however a high potential for various biases that we tried to address with adequate measure. One limitation however cannot be overcome: The methodologically needed age-limitation of the study will make it not easy to generalize the results to age groups over 50 years. It might be suggested to repeat the study for persons over 50 years in 10 years when contamination with phenacetin use early in life is likely to be outgrown.

Figures

Figure 1
Figure 1
Index dates and relationship with putative analgesic use in the SAN case-control study.

References

    1. Dubach UC, Levy PS, Minder F. Epidemiological study of analgesic intake and its relationship to urinary tract disorders in Switzerland. Helv Med Acta. 1968;34:297–312.
    1. Grimlund K. In: Phenacetin and renal damage at a Swedish factory. Kungl. ktryckeriet Bo, editor. PA. Norstedt & Söner, Stockholm; 1963.
    1. Delzell E, Shapiro S. A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine. 1998;77:102–21. doi: 10.1097/00005792-199803000-00003.
    1. McLaughlin JK, Lipworth L, Wong-Ho C, Blot WJ. Analgesic use and chronic renal failure: A critical review of the epidemiologic literature. Kidney International. 1998;54:679–686. doi: 10.1046/j.1523-1755.1998.00043.x.
    1. Feinstein AR, Heinemann LAJ, Curhan GC, Delzell E, DeSchepper PJ, Fox JM, Graf H, Luft FC, Michielsen P, Mihatsch MJ, Suissa S, Van der Woude F, Willich S, (ad-hoc review committee) The relationship between non-phenacetin combined analegesics and nephropathy: A review. Kidney Internat. 2000;58:2259–2264. doi: 10.1046/j.1523-1755.2000.00410.x.
    1. Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther. 2000;22:500–548. doi: 10.1016/S0149-2918(00)80043-0.
    1. Feinstein AR, Heinemann LAJ, Dalessio D, Fox JM, Goldstein J, Haag G, Ladewig D, O'Brien CP. Do Caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther. 2000;68:457–467. doi: 10.1067/mcp.2000.110974.
    1. Fox JM, Siebers U. Caffeine as a promotor of analgesic-associated nephropathy – where is the evidence? Fundamental & Clinical Pharmacology. 2003;17:377–92. doi: 10.1046/j.1472-8206.2003.00174.x.
    1. Greiser E, Molzahn M, eds . Multizentrische Nieren- und Urothel-Carcinom-Studie (Abschlußbericht). Schriftenreihe der Bundesanstalt für Arbeitsschutz und Arbeitsmedizin Fb 780. Wirtschaftsverlag NW, Bremerhaven; 1998.
    1. Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol. 1989;9:403–12.
    1. McCredie M, Stewart JH, Mahony JF. Is phenacetin responsible for analgesic nephropathy in New South Wales. Clin Nephrol. 1982;17:134–40.
    1. Morlans M, LaPorte J, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol. 1990;30:717–723.
    1. Sandler DP, Smith JC, Weinberg CR, Buckalew VM, Dennis VW, et al. Analgesic use and chronic renal disease. N Engl J Med. 1989;320:1238–43.

Source: PubMed

3
Suscribir